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Thrombotic microangiopathy, which includes thrombotic
thrombocytopenic purpura (TTP), shiga-toxin-associated
hemolytic uremic syndrome (Stx-HUS) and atypical HUS, is
characterized by the development of hyaline thrombi in the
microvasculature resulting in thrombocytopenia,
microangiopathic hemolysis, and organ dysfunction. Renal
failure is a predominant complication of both Stx-HUS and
atypical HUS, whereas neurological complications are more
prominent in TTP. Other disorders such as lupus or bone
marrow transplantations may occasionally present with
features of thrombotic microangiopathy. Recent studies have
found autoimmune inhibitors or genetic mutations of a von
Willebrand factor (VWF) cleaving metalloprotease ADAMTS13
in patients with TTP. In approximately 30–50% of patients
with atypical HUS, mutations have been detected in
complement factor H, membrane cofactor protein (CD46), or
factor I. All three proteins are involved in the regulation of
complement activation. Additionally, autoantibodies of factor
H have been described in patients without genetic
mutations. These advances illustrate that dysregulation of
VWF homeostasis or complement activation owing to genetic
or autoimmune mechanisms may lead to the syndrome of
thrombotic microangiopathy.
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Thrombotic microangiopathy is a clinico-pathological
syndrome consisting of hyaline thrombi in the microvas-
culature of various organs and the presence of fragmented
red blood cells and thrombocytopenia in the peripheral
blood. Widespread thrombosis in the microcirculation causes
consumptive thrombocytopenia and creates abnormally high
levels of shear stress that fragment the red blood cells. The
thrombosis often affects the brain, kidney, heart, and other
vital organs.
Thrombotic thrombocytopenic purpura (TTP) is a
relatively uncommon yet intriguing disorder that frequently
presents mysteriously and abruptly with the development
of von Willebrand factor (VWF) and platelet-rich thrombi
in the arterioles and capillaries of brain, heart, and other
organs. Neurological and renal abnormalities such as
confusion, focal neurological deficits, seizures, hematuria,
and proteinuria are common. Nevertheless, hypertension or
advanced renal failure requiring dialysis is rare in TTP.
Without treatment, the disease is associated with a very
high mortality rate (490%). When treated with plasma
infusion or plasma exchange, 70–90% of the patients survive
the acute episodes. However, relapse occurs in more than
one-third of the patients who achieve remission, contribut-
ing to further morbidity and mortality. A subset of
patients develops chronic TTP, requiring long-term plasma
exchange.
Initially described as a distinct uremic disorder follow-
ing a prodrome of hemorrhagic diarrhea, the hemo-
lytic uremic syndrome (HUS) has been closely intertwined
with TTP, as evidenced by frequent use of the hybrid term
TTP/HUS in the literature. HUS has also been extended
to include atypical cases that are not preceded by a
diarrheal prodrome. Other conditions such as systemic
lupus erythematosus, bone marrow or solid organ trans-
plants, chemotherapeutic or other medications, disseminated
intravascular coagulopathy, and metastasizing malignancies
may occasionally be complicated with the syndrome of
thrombotic microangiopathy with variable renal and neuro-
logical involvement.
Recent studies have delineated the molecular defects of
TTP and some of the atypical HUS cases, demonstrating that
the syndrome of thrombotic microangiopathy may result
from distinct pathogenetic processes. This article reviews the
critical advances in the studies of TTP and HUS.
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THROMBOTIC THROMBOCYTOPENIC PURPURA
VWF and hemostasis in the microcirculation
VWF, a glycoprotein synthesized in vascular endothelial cells
and megakaryocytes, supports platelet adhesion and aggrega-
tion at sites of vessel injury under high shear stresses. This
unique property of VWF is believed to result from its large
molecular structure that is conformationally flexible in
response to shear stress. When VWF is attached to blood
vessel matrix components at a site of injury, it is exposed to
high levels of shear stress at the boundary between the
flowing blood and the vessel wall, which unfold the
conformation of VWF from a globular to an elongated form,
providing the substrate to support platelet adhesion and
aggregation. As large multimers are conformationally more
responsive to shear stress than small multimers, the size of
VWF multimers is a major determinant of VWF activity.
Deficiency of VWF, particularly the large multimers, causes
hemorrhagic diathesis characterized by mucocutaneous
capillary bleeding.
The process of conformational unfolding also occurs
after a VWF molecule enters the circulation. However, since
VWF is exposed to high shear stresses only very briefly
during each cycle of passage through the microcirculation,
the conformational change is much less efficient once a VWF
molecule enters the circulation. ADAMTS13, a circulating
zinc metalloprotease, cleaves VWF whenever one or more
of its cleavage sites are exposed by shear stress. This proteo-
lysis converts endothelial-derived high molecular weight
VWF polymer to a series of disulfide-bonded multimers as
observed in the plasma samples. Deficiency of ADAMTS13
leads to a shift of plasma VWF multimers to larger sizes.
Most importantly, in the absence of ADAMTS13, endothelial
secreted VWF polymer and the large multimers in the
circulation will eventually become fully unfolded by shear
stress to become elongated forms, creating an environment
favoring VWF–platelet binding, platelet aggregation, and
microvascular thrombosis. The complex interaction among
VWF, platelet, ADAMTS13, and shear stress is depicted in
Figure 1.1
The process of VWF–platelet binding promoted by
ADAMTS13 deficiency is likely to be affected by multiple
factors such as the shear stress profile in the microvascu-
lature, the reactivity of platelets, and the rate of VWF release
from microvascular endothelial cells. Despite these com-
pounding factors, serial investigation of individual TTP
cases often detects a clear inverse correlation between
the ADAMTS13 activity level and the VWF-platelet binding,
as represented by the severity of thrombocytopenia and
depletion of ultra-large and large VWF multimers. In our
experience, when ADAMTS levels decrease below 15–20% of
normal level, a shift of the VWF multimers to larger sizes
is detectable by SDS agarose gel electrophoresis. Further
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Figure 1 | Schematic depiction of TTP owing to ADAMTS13 deficiency. (a) When a large VWF multimer is attached to the extracellular
matrix at a site of injury, it is conformationally unfolded by high levels of wall shear stress to an elongated form, providing the substrate
for platelets adhesion and hemostasis. (b) In the normal circulation, VWF and platelets do not interact to form aggregates because
ADAMTS13 cleaves the VWF multimer whenever one or more of its cleavage sites are exposed by shear stress. This process keeps VWF
in inactive, globular forms as it become progressively smaller in size. (c) In the absence of ADAMTS13, VWF multimers eventually become
fully unfolded by shear stress, causing intravascular platelet thrombosis characteristic of TTP.
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decrease of ADAMTS13 activity below 10% of normal begins
to result in clinically apparent thrombosis, thrombo-
cytopenia, and progressive depletion of the large multimers.
The threshold values cited here may differ when other
versions of ADAMTS13 assays are used.
Recently, several studies have demonstrated that when
endothelial cells are exposed to cytoactive molecules such as
histamine or calcium ionophore A23187, the secreted VWF
may remain anchored to endothelial surface, providing a
substrate to support platelet adhesion.2–4 ADAMTS13 causes
detachment of the adherent platelets, presumably by cleaving
the anchored VWF. In the absence of ADAMTS13, these
platelet strands tend to persist. It remains to be determined
whether this process may contribute to the exacerbation of
TTP in association with the stresses of infection, surgery, or
pregnancy.
Structure and function of ADAMTS13
ADAMTS13 belongs to a family of extracellular, multi-
domain zinc metalloproteases in which the catalytic metallo-
protease domain with a zinc-binding active-site motif is
similar to that of ADAM proteases and is followed by a
disintegrin-like domain, a central thrombospondin type 1
repeat (TSR), a cysteine-rich domain, a cysteine-free spacer
domain, and usually one or more TSRs (Table 1 and
Figure 2). ADAMTS13 is constitutively active in the
circulation with a narrow range of activity (79–127%) in
normal individuals. Recombinant expression studies reveal
that ADAMTS13 constructs truncated at the central TSR
domain retain a small fraction of VWF-cleaving activity.5
The addition of the cysteine-rich and the spacer domains
markedly increases the proteolytic potency to approxi-
mately 50% of the full-length enzyme. As the spacer domain
is essential for interaction with the anti-ADAMTS13
antibodies of TTP, ADAMTS13 variants devoid of the spacer
domain are not recognized or suppressed by TTP immu-
noglobulin G (IgG) antibodies. Such non-suppressible
ADAMTS13 variants may be exploited to circumvent the
therapeutic difficulties of TTP posed by anti-ADAMTS13
antibodies.5
ADAMTS13 deficiency and TTP
Several large series of cases have confirmed the prevalence of
ADAMTS13 deficiency among patients with the acquired
form of TTP, as reviewed elsewhere.1 The percentage of
patients with ADAMTS13 deficiency ranges from 13 to 100%.
This variation in prevalence is attributable to at least two
reasons: the stringency of the criteria for defining the study
cases and the assay used to measure ADAMTS13 activity. In
some studies, the cases were classified based on the diagnosis
provided by the referring physicians or the findings at the
time of presentation. Such series invariably included patients
without TTP. When a patient appears to have TTP without
ADAMTS13 deficiency, it is imperative to investigate the
presence of an underlying cause that is not apparent at the
time of presentation. In our experience, such unapparent
causes may include systemic lupus erythematosus or related
disorders, occult metastatic cancers, paroxysmal nocturnal
hemoglobinuria with widespread mesenteric microvascular
thrombosis, and atypical HUS. These conditions require
different therapeutic approaches targeted to the specific
causes.
Table 1 | Characteristics of proteins involved in the pathogenesis of TTP and atypical HUS
Protein ADAMTS13 Complement factor H Complement factor I (IF) Membrane cofactor protein
Gene, RefSeq NM_139026 NM_000186 NM_000204 NM_002389
Genomic size (kb) 37 95 63 43
Location 9q34 1q32 4q25 1q32
No. of exons 29 23 13 14
cDNA size (kb) 4.7 4.0 2.0 3.4
Amino-acid residues
(precursor)
1427 1231 583 392
Mol wt (kDa)
Predicted 154 139 65.7 43.7
Observed 190 155 88 59–68 (BC1, BC2)
43 (50 & 38) 51–58 (C1, C2)
Tissue expression Liver (stellate cells) Liver Liver, EC, MNC, etc. Kidney, fetal heart, brain,
MNC, spermatozoa
Subcellular location Plasma Plasma Plasma Transmembrane protein
Plasma concentration 1 mg/mla 3.5 mg/ml 35mg/ml —
Function Cleavage of sheared VWF Co-factor of IF
k Alternative C3 convertase
Cleavage of C3b, C4b Co-factor of IF
Activation of Treg
Causes of deficiency Inhibitory antibodies
Genetic mutations
Autoantibody
Genetic mutations Genetic mutations Genetic mutations
Disorders of deficiency TTP MPGN
Atypical HUS
Pyogenic infection
Vasculitis Atypical HUS
Atypical HUS
HUS: hemolytic uremic syndrome; EC: endothelial cell; MNC: mononuclear cells; MPGN: membrano-proliferative glomerulonephropathy; TTP: thrombotic thrombocytopenic
purpura; Treg: regulatory T cells.
aEstimated.
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Different ADAMTS13 assays have yielded opposite results
in some cases, one of which has been described.6 This and
other similar incidences should serve as a precaution that
each assay result needs to be carefully scrutinized and
corroborated with clinical and laboratory data. VWF multi-
mer analysis by agarose gel electrophoresis or VWF
proteolytic profiling by polyacrylamide gel analysis may be
particularly helpful in identifying inconsistent assay results.
Two types of ADAMTS13 deficiency have been recognized:
autoimmune IgG inhibitors of ADAMTS13 and mutations of
the ADAMTS13 gene. Autoimmune inhibitors account for
490% cases of ADAMTS13 deficiency.
Hereditary deficiency of ADAMTS13. More than 55 muta-
tion of the ADAMTS13 gene have been described from 460
patients with the inherited forms of TTP.1 One mutation,
4143insA, has been detected in both homozygous and
heterozygous forms in multiple pedigrees from Europe,
suggesting that they may have common ancestry. In addition
to mutations, at least 26 polymorphisms have been described
in the ADAMTS13 gene. The polymorphisms may not
be entirely benign, as some have been shown to affect
ADAMTS13 expression depending on the sequence con-
text.7,8
The patients usually present during the neonatal period
with periodic episodes of thrombocytopenia and micro-
angiopathic hemolysis that improve quickly upon infusion
of plasma infusion. In patients with less severe disease, TTP
may first presents later in life and relapse sporadically. In
our series of 25 cases of hereditary TTP, 30% had chronic
neurological deficits due to ischemic strokes or kernicterus.
Acute renal failure occurred at least once in 5 cases. However,
it was reversible in each case after the patient was promptly
treated with plasma therapy. Chronic renal failure has been
described in patients with inherited TTP that did not receive
periodic plasma infusion. Furthermore, one case of heriditary
TTP has been described that developed chronic renal failure
due to a concurrent factor H mutation.9 Long-term plasma
infusion is an effective but challenging therapy for hereditary
TTP mutations
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Figure 2 | Schematic depiction of the domain structures of proteins involved in the pathogenesis of TTP and atypical HUS.
(a) ADAMTS13. Sig: signal peptide; PrP: propeptide; MP: metalloprotease domain; Cys: cysteine-rich region; and TSR: thrombospondin type 1
repeat. The amino-acid sequence of the zinc-binding motif in the MP domain and the RGDS sequence in the cysteine-rich region are shown.
Brackets indicate the segments exhibiting VWF cleaving activity or binding with the IgG of TTP. Mutations of ADAMTS13 have been detected
throughout the entire span of the protein. (b) Factor H. The protein consists of 20 complement control protein repeats (CCPR). The three C3b
binding sites and three polyanion binding domains are indicated. The first C3b binding site (gray) has co-factor activity for IF. The major
polyanion-binding site at CCPR20 is highlighted in black. The majority of the mutations associated with HUS cluster at the C-terminal end,
particularly CCPR20, which is critical for host binding. (c) Complement IF. The single-chain precursor form is depicted. FIMAC: factor I major
attack complex; Kazal_2: Kazal-type serine protease inhibitor domain; SRCR: scavenger receptor cysteine-rich domain; LDLR-A: LDL receptor
domain class A; and Trypsin: trypsin-type protease domain. Four mutations have been detected in the protease domain of the protein. (d) MCP
(membrane co-factor protein). CCPR: complement control protein repeat. STP: serine/threonine/proline-rich domain; TM: transmembranous
domain; and Tail: cytoplasmic anchor. The region of the protein critical for C3b binding and cofactor activity is highlighted in the bracket. HUS
mutations have been detected in CCPR4.
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TTP. The risk of serious complications and the possible co-
existence of other disorders should be taken into considera-
tion when individual cases are evaluated for therapeutic
options.
Acquired deficiency of ADAMTS13. Plasma mixing studies
have detected the presence of inhibitory antibodies of
ADAMTS13 in 50–90% of the acquired TTP cases.1 In
patients whose inhibitory antibodies are too low to be detect-
able by plasma mixing studies, IgG isolated from the plasma
samples may yield positive inhibition. Anti-ADAMTS13
antibody is detectable by enzyme-linked immunosorbent
assay in 97–100% of the patients with acquired ADAMTS13
deficiency.10,11 Nevertheless, the enzyme-linked immuno-
sorbent assay may yield false-positive results in 5–15% of the
general population without TTP. These false-positive cases
can be identified by adding ADAMTS13 protein, which
blocks the binding of anti-ADAMTS13 IgG but not of the
nonspecific IgG.11
The etiologies of ADAMTS13 inhibitory antibodies are
unknown in most cases. The widespread use of ticlopidine
in the 1990s was accompanied by a surge of TTP in
approximately 1 per 2000–4000 patients treated, which
represents an increase by at least 65- to 130- fold over the
background incidence. HIV infection may also increase the
risk of TTP.
Plasma exchange is believed to control thrombosis by
replenishing the missing enzyme until the endogenous
ADAMTS13 recovers over the waning inhibitors. Many
patients continue to have decreased ADAMTS13 activity
levels during remission, indicating that the immune response
does not subside completely and the patients are at risk of
relapse. In chronic TTP, the ADAMTS13 inhibitors persist
at higher levels, preventing the recovery of endogenous
ADAMTS13 to detectable levels. In such patients, rituximab,
a chimeric anti-CD20 monoclonal antibody, has been used to
deplete the B cells and induce remission of TTP. The efficacy
of rituximab therapy in patients with chronic refractory TTP
has prompted investigators to study its use in patients with
acute TTP or a history of TTP with multiple relapses. As the
course of TTP is unpredictable, the role of rituximab requires
rigorous investigation in such cases.
Animal model of ADAMTS13 deficiency
ADAMTS13-deficient mice generated by gene targeting
are viable without disease manifestations (Table 2).3 Crossing
of the mice to the genetic background of the CASA/Rk
strain results in the appearance of spontaneous TTP-like
hyaline thrombi and decreased survival in a subset of the
ADAMTS13-deficient mice. The C57BL/6J strain of mice
used in generating the ADAMTS13-null founder allele
primarily express a form of ADAMTS13 truncated after the
sixth TSR motif, whereas the CASA/Rk strain expresses the
full-length form. It is speculated that the wild-type C57BL/6J
mice may harbor mutations that compensate for the relative
ADAMTS13 deficiency. Genetic cross onto the CASA/Rk
strain might lose the protective mutations, leading to the
emergence of the TTP phenotype in the ADAMTS13-
deficient mice. Further investigation of the protective genes
in C57BL/6J strain of mice against TTP may provide clues for
understanding the variation of disease severity in TTP.
SHIGA-TOXIN-ASSOCIATED HEMOLYTIC UREMIC SYNDROME
Shiga-toxin-associated hemolytic uremic syndrome (Stx-HUS)
is characterized by microvascular thrombi in the kidney.
Other organs may also be affected with thrombosis in severe
cases. Most cases of post-diarrhea HUS are caused by shiga
Table 2 | Animal models of TTP and HUS
Authors Host Findings
ADAMTS13
Motto et al. (2005) Mouse No phenotype in the founder strain with mixed C57BL/6J and 129X1/SvJ genetic background.
Spontaneous TTP in mice with CASA/Rk genetic background.
Stx-2 precipitates TTP in ADAMTS13-null mice with CASA/Rk background.
STEC or Shiga toxins (Stx-1 or Stx-2)
Tesh et al. (1993) Mouse Stx causes proteinuria, necrosis of renal tubular cells, and death.
Stx-2 is more potent than Stx-1
No thrombotic microangiopathy
Shibolet et al. (1997) Rat (kidney) Perfusion of kidney with Shiga toxin causes direct renal tubular necrosis
Yamamoto et al. (2005) Rat (kidney) Renal tubular necrosis, glomerular platelet aggregates, apoptosis, and TNF-a expression in the
medulla
Woods et al. (2002) Ferret Renal thrombotic microangiopathy
Gunzer et al. (2002) Gnotobiotic piglet Colitis, renal thrombotic microangiopathy, and myelin sheath degeneration
Siegler et al. (2003) Baboon Stx-2 more potent than Stx-1 in causing HUS
Raife et al. (2004) Greyhound dog Thrombotic microangiopathy of the kidney and skin in natural cases
Lepirudin may prevent the lethal effect of Stx-2 in experimental animals
Factor H
Hogasen et al. (1995) Pig Homozygous deficiency causes MPGN
Pickering et al. (2002) Mouse Homozygous deficiency causes MPGN
Abbrevations: HSU: hemolytic uremic syndrome; MPGN: Membrano-proliferative glomerulonephropathy; STEC: Shiga toxin producing E. coil; TNF-a: tumor necrosis factor a;
TTP: thrombotic thrombocytopenic purpura.
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toxin-producing Escherichia coli O157:H7 or S dysenteriae
serotype 1. The history, epidemiology, molecular microbio-
logy, clinical presentation, and management of Stx-HUS
have been expertly reviewed recently.12 A typical case
develops thrombocytopenia, microangiopathic hemolysis,
and azotemia 1 week after having diarrhea owing to infection
with E. coli O157:H7. Occasionally, the diarrheal prodrome
may not be evident.
Many strains of shiga toxin-producing E. coli found in
animal reservoir have not been associated with the develop-
ment of hemorrhagic diarrhea or HUS, indicating that other
features of the organisms are necessary for virulence. Most
cases of colitis or HUS are infected with E. coli of the shiga
toxin 2 genotype, which is 56% homologous to the genes of
shiga toxin 1. Although shiga toxin 2 binds less avidly than
shiga toxin 1 to glycolipid cell surface receptor globotriao-
cylceramide (Gb3), shiga toxin 2 is more stable in the acidic
environment of endosomes, and therefore is more likely
to inhibit the eEF-1-dependent binding of aminoacyl tRNA
to the 60S subunit of ribosomes. The resulting inhibition
of protein synthesis is cytotoxic to the target cells such as
glomerular endothelial cells. Endothelial cell injury and
detachment expose the underlying thrombogenic glomerular
basement membrane, causing activation of platelets and
the coagulation cascade.13 This sequence of events is further
supported by the findings of endothelial swelling and
detachment, platelet–basement membrane attachment, and
fibrin clots observed in the lesions of human and animal
HUS. Shiga toxins may also be cytotoxic to glomerular
mesangial cells and renal tubular cells, contributing to the
severity of renal dysfunction. Other studies have demons-
trated that shiga toxins may increase the endothelial
expression of adhesion molecules such as E-selectin, inter-
cellular adhesion molecule-1, vascular cell adhesion mole-
cule-1, P-selectin, glycoprotein avb3, and platelet cell
adhesion molecule-1, promoting the adhesion of leukocytes
and platelets. Shiga toxins may also increase the expression of
interleukin IL-6 and monocyte chemoattractant protein 1 in
the kidney and of tumor necrosis factor a and interleukin-1b
in monocytes/macrophages. The latter cytokines may
upregulate the expression of Gb3 receptors on endothelial
cells, thereby rendering the cells more susceptible to the
cytotoxic effects of shiga toxins. Lipopolysaccharide from
the microorganisms may also augment the pathogenesis of
shiga toxins, perhaps via its effects on the expression of
inflammatory cytokines.
With perhaps a few exceptions, patients with E. coli
O157:H7 or diarrhea-associated HUS have normal ADAMTS13
activity levels and no inhibitory antibodies. In contrast to the
lesions of TTP, the thrombi in the renal glomeruli of Stx-HUS
contain fibrin and no or little VWF.14 In the presence of
ADAMTS13, abnormal shear stress created by microvascular
thrombosis enhances the cleavage of VWF, shifting its size to
smaller multimers. The difference in ADAMTS13, VWF, and
pathological features clearly indicates that Stx-HUS and TTP
are distinct in pathogenesis.
Animal model of Stx-HUS
Both Stx-producing E. coli and purified shiga toxins have
been administered to various animal models. Thrombotic
microangiopathy is detected in ferrets, gnotobiotic piglets,
baboons, and greyhound dogs, but not in mice or rats,
although Stx may cause direct renal tubular necrosis and
acute renal failure in these animals (Table 2). Interestingly,
intravenous shiga toxin 2 injection caused a TTP-like disease
in ADAMTS13-deficient mice of the CASA/Rk strain,
with VWF-rich thrombi detected in multiple organs.3 In
another study, high concentrations of shiga toxin 1 induce
rapid release of VWF from cultured vascular endothelial
cells and slightly delay the ADAMTS13-induced detachment
of adherent platelets.15 Together, these observations suggest
that shiga toxins may precipitate the development of TTP in
ADAMTS13-deficient mice by promoting VWF secretion and
VWF–platelet thrombus formation on endothelial surface.
Further studies are necessary to delineate the relevance
of these observations to the pathogenesis of human TTP
or HUS.
ATYPICAL HEMOLYTIC UREMIC SYNDROME
The disorder of atypical HUS occurs in individuals without
TTP, prodromal infection with Stx-producing microorgan-
isms, or other obvious etiologies. Occasionally, a diarrheal
illness or infection may trigger the onset of HUS. Atypical
HUS may be genetically transmitted and is recurrent in most
cases. The thrombocytopenia in HUS is not as closely linked
to the severity of disease as in TTP. Mental change or seizures
may occur. The course of renal function is quite unpredict-
able. Some of the cases have advanced, irreversible renal
failure at the first presentation. Others fully recover the renal
function. In still other cases, renal function recovers, but
subsequently deteriorates without relapsing hematological
complications. Occasionally, a patient presents with HUS
only after receiving a renal graft for end-stage renal failure.
Hypertension and fluid overload are common and may be
severe during the acute phase of atypical HUS. Hypertension
often persists after the hematological abnormalities have
remitted. As TTP overlaps with HUS in the severity of renal
dysfunctions or neurological abnormalities, ADAMTS13
analysis may be needed to exclude the diagnosis of TTP in
suspected cases. Before ADAMTS13 analysis became avail-
able, some patients with TTP received the diagnosis of
atypical HUS because they had prominent renal failure.
Table 3 compares the features of hereditary HUS with that of
hereditary TTP.
Molecular basis of atypical HUS
Mutations in one of three proteins involved in the regulation
of complement activation (Table 1 and Figure 2) have been
identified in approximately 30–50% of both familial and
sporadic atypical HUS patients.16,17 Two of these proteins,
complement factor H (CFH) and membrane co-factor
protein (MCP; or CD46) are members of the regulators of
complement activation cluster located on chromosome 1q32.
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Both proteins are co-factors of complement factor I (IF),
which is a circulating serine protease that cleaves and
inactivates surface-bound C3b and C4b in the presence of
co-factors. Furthermore, CFH antibodies have been detected
in three patients without mutations in CFH, MCP, or IF.18
Together, defects in these proteins provide direct evidence
that in a subset of patients, uncontrolled complement
activation resulting from dysregulation of C3 cleavage plays
an important role in the pathogenesis of HUS (Figure 3).
HUS owing to a mutation in the CFH, IF, or MCP is
transmitted as an autosomally dominant trait with consider-
able variability in penetrance. Further complicating the
association of CFH or IF deficiency with HUS, patients with
severe CFH deficiency may develop membrano-glomerulone-
phropathy without HUS.19,20 Separately, more than 20 cases
of severe IF deficiency have been described from 19 pedigrees
that are characterized by increased risk of pyogenic infection,
but no apparent risk of HUS or renal failure.21 The reasons for
the phenotypic variation in these patients remain unknown.
Haplotype analysis suggests that the risk of atypical HUS
may be linked to CFH and MCP even in those without
a detectable mutation in either gene.17 Concurrent genetic
variations in the regulators of complement activation further
increase the risk of developing HUS.
Diagnosis and treatment of atypical HUS
Diagnosis of deficiencies in the complement regulatory
proteins often requires extensive investigative studies.
Measurement of protein levels in blood samples may yield
suggestive or informative results: a defective regulation of C3
cleavage may decrease the C3 level as a consequence of
alternative pathway complement consumption; the levels of
the mutant proteins may be decreased in the serum or blood
cells; and some of the factor H mutants display unusual
mobility in the electrophoresis. However, complement
activation is not always present, and some of the mutations
do not affect the expression of the dysfunctional proteins.
Therefore, detailed genetic and functional analyses are often
necessary to demonstrate the involvement of a complement
regulator in the pathogenesis of HUS.
The outcome of atypical HUS remains dismal for many
patients that require dialysis or renal transplantation.
Anecdotally, some of the patients with atypical HUS improve
in response to plasma infusion or exchange. It is conceivable
that plasma therapy may benefit patients with mutations or
antibodies of CFH or IF by replenishing the missing protein
or removing the antibodies. Nevertheless, even after initial
Table 3 | Clinical features of hereditary TTP and hemolytic uremic syndrome
Disorder Hereditary TTP Hereditary atypical HUS
Gene affected ADAMTS13 CFH IF MCP
No. of cases 460 450 4 13
Location of mutations Entire ADAMTS13 gene CCPR 18–20: 63% Trypsin domain CCPR4
Inheritance Recessive Dominant with variable penetrance
Age affected, (years) Newborn–adult Newborn–adult Newborn–adult Child–adult
Neurological complications Common Less common Less common Less common
Hypertension Rare Common Common Common
Acute renal failure Occasional Yes Yes Yes
Chronic renal failure Uncommon Common Common Common (4/9)
Diagnosis ADAMTS13 o10% Factor H assay Factor I assay MCP assay
Parents: partial deficiency Genetic study Genetic study Genetic study
Genetic study
Plasma infusion Effective (every 2–3 weeks) Probably effective, optimal regimen unknown Probably ineffective?
Relapse after renal transplant Renal transplant not needed Yes Yes No (0 of 3 cases)
Animal model Yes Yes (MPGN) No No
CCPR: Complement control protein repeat; CFH: complement factor H; HUS: hemolytic uremic syndrome; IF: complement factor I; MCP: membrane co-factor protein; MPGN:
Membranoproliferative glomerulonephropathy; TTP: thrombotic thrombocytopenic purpura.
Mutation or autoantibody of CFH, IF, or MCP
Defective CFH, IF, or MCP
C3b not inactivated
Complement pathway activation
C3a, C5a, C5b9 ↓ Complement factors
Renal cell injury
Renal failure Thrombosis ↑ Shear stress
Thrombocytopenia RBC fragmentation
Risk of infectionEndothelial injury
Figure 3 | A pathogenetic scheme of atypical HUS owing to
complement dysregulation. Mutation or autoantibodies of
complement factor H (CFH), factor I (IF), or membrane cofactor
protein (MCP, or CD46) cause defective regulation of the alternative
pathway. Excessive complement activation generates cytoactive
molecules, such as C3a, C5a, and C5b9, which injure both renal
parenchymal and endothelial cells. Endothelial injury may create a
prothrombotic state, leading to local accumulation of platelet–fibrin
thrombi. Thrombocytopenia and hemolysis are apparent only when
microvascular thrombosis is widespread. In the absence of HUS,
renal parenchymal injury may continue to occur, leading to the
development of renal failure. Incessant complement activation
may increase the risk of pyogenic infection by depleting essential
complement components.
22 Kidney International (2006) 70, 16–23
m i n i r e v i e w H-M Tsai: Thrombotic microangiopathy
improvement with plasma therapy, some of the responding
patients go on to develop advanced renal failure. Further-
more, except in patients with MCP defects, relapse of HUS is
common after renal transplantation. Experimental and
clinical evidence suggests that unregulated activation of the
alternative complement pathway causes both renal paren-
chymal and vascular injuries (Figure 3). The florid hemato-
logical consequences of vascular injury may have hampered a
full appreciation of the role of renal parenchymal cell injury.
In fact, it is conceivable that the syndrome of HUS only
develops when vascular injury causes extensive micro-
thrombosis. Renal parenchymal injury may continue to
occur in the absence of thrombocytopenia or microangio-
pathic hemolysis. This scheme may explain why some
patients develop advanced renal failure without episodes of
HUS, and suggests that the practice of instituting plasma
therapy only during episodes of HUS is inadequate for such
patients. Thus, it will be important in future studies to
explore whether long-term plasma or factor replacement
therapy during the periods of hematological remission
improves the prognosis of patients with defects in CFH or IF.
Animal models of atypical HUS
A porcine and a murine model of factor H deficiency
have been described (Table 2). In these animals, factor H
deficiency causes membrano-glomerulonephropathy without
evidence of thrombotic microangiopathy.
PROSPECTIVE
Until recently, physicians instituted plasma therapy for
patients of TTP or HUS without knowing its mechanisms
of action. The identification of the molecular defects
underlying the pathogenesis of TTP and atypical HUS is
beginning to impact on the diagnosis and treatment of the
diseases. As specific tests are more reliable and widely
available, the nature and course of the diseases are becoming
better delineated. Already, therapeutic options are being
tailored based on individual molecular defects. It should be
feasible in the future to replace plasma therapy or renal
transplantation with bioengineered proteins or gene/cell
therapies. There is interesting experimental evidence that
bioengineered ADAMTS13 variants may help overcome the
therapeutic barriers imposed by ADAMTS13 inhibitors.5
Both the hereditary and acquired forms of TTP and HUS
shows considerable variability in severity, suggesting that
genetic and environmental factors play important roles in
modifying the expression of the diseases. It will be critical in
future studies to elucidate the nature of these modifiers. The
animal models will be invaluable in providing information
that is difficult or impossible to obtain from human subjects.
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